An Open Label Study to Compare the Oral Bioavailability of a Tablet of GLPG1690 Relative to a Capsule After Single-dose Intake in Healthy Subjects and to Evaluate the Effect of Food on the Tablet
Latest Information Update: 26 Apr 2019
At a glance
- Drugs Ziritaxestat (Primary)
- Indications Idiopathic pulmonary fibrosis; Systemic scleroderma
- Focus Pharmacokinetics
- Sponsors Galapagos NV
- 23 Apr 2019 Results assessing the Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects in Phase 1 Randomized Trials, published in the Journal of Clinical Pharmacology
- 19 Jun 2017 Status changed from recruiting to completed.
- 10 May 2017 New trial record